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Conclusions: In this series of patients undergoing TAVR and having sequential BNP
measurements, baseline BNP did not predict survival, but BNP decreasing by more than
2000 pg/ml 30 days after TAVR was a strong predictor of survival.
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Background: To serve as comparative data for percutaneous replacement, the purpose of
this study was to characterize the historical outcomes for aortic and mitral valve
replacement surgery in a large, nationally representative patient population.
Methods: Patients undergoing aortic or mitral valve replacement were identified from the
5% national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The
subsequent rates of mortality, mechanical complications, infection, and valve re-
implantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedure were also
assessed.
Results: The patient cohort included 12,202 aortic bioprosthesis, 9,757 aortic
mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic
mechanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively.
The corresponding ten-year Kaplan-Meier rates for mitral bioprosthesis were
74.8%, 8.02%, 6.29%, 2.81%, and 12.90%, respectively, and for mitral mechan-
ical valves were 64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The
average hospitalization reimbursements for procedures involving aortic biopros-
theses, aortic mechanical valves, mitral bioprostheses, and mitral mechanical
valves were $54.3k, $54.6k, $64.1k, and $62.2k, respectively.
Conclusions: The crude risk of mortality and complications, as well as payer costs, were
found to be higher for mitral valve replacements compared with aortic valve replace-
ments. This study provides baseline data for evaluating the comparative effectiveness of
percutaneous valve replacement to “traditional” approaches, especially since the percu-
taneous approach may have inherently different levels of performance or expanded
indications.
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Background: Long-standing aortic stenosis (AS) causes left ventricular (LV)
dysfunction, which may improve after trans-catheter aortic valve implantation
(TAVI). The LV subendocardium is composed of longitudinal fibres which are
highly sensitive to ischaemia caused by high LV filling pressures. Measurement
of long axis systolic amplitude is an easy measure of subendocardial function. The
aim of this study was to assess the nature of subendocardial abnormalities in AS
and their response to TAVI.
Methods: We studied 46 consecutive patients (age 827 years) with severe AS
but no flow-limiting coronary artery disease, one week before and 6 months after
TAVI. LV ejection fraction (LVEF) was calculated using Simpsons biplane
methods. LV subendocardial dysfunction was studied from long axis M-mode
amplitude at the lateral, septal, and posterior sites. Systolic amplitide was
measured as displacement of the mitral ring between the q wave of the ECG to
aortic valve closure. Incoordination (post-ejection shortening: PES) was measured
as amplitude of further inward motion after aortic valve closure. LV diastolic
function was assessed by mitral filling velocities (early diastolic: E wave, and late
diastolic: A wave). Averaged values for lateral, septal, and posterior sites are
presented, and values were compared to 17 normal controls.
Results: In controls, LVEF was 657%, long axis systolic amplitude and velocity
were 143mm and 72cm/s, there was no PES, and E:A ratio was 1.00.3. In
patients before TAVI, LVEF, long axis systolic amplitide and velocities were
lower than controls (4619%, 6.52.1mm, 4.11.9cm/s respectively), PES was
present (31mm) and E:A was higher than controls (3.34.6, all p0.01). After
TAVI, LVEF did not change (4917%), but long axis systolic amplitide and
velocities increased (to 9.22.3mm, and 6.72.1cm/s); PES increased (to
52mm) and E:A ratio fell (to 2.11.4).
Conclusions: Relief of AS following TAVI causes improvement in LV subendo-
cardial function manifest as increased long axis systolic amplitude and velocity.
However reduction in LV-EDP also permits appearance of incoordination, with
associated abnormal diastolic function, that may require exclusion of epicardial
coronary obstruction.
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Background: Advances in cardiovascular care has a significant impact on changing the
landscape of valvular heart disease. Balloon aortic valvuloplasty (BAV) considered to be
of palliative role become of essential importance in the era of TAVI. Patients with severe
aortic stenosis and poor surgical candidacy not yet qualifying for TAVI still require BAV
as a main therapeutic tool. The hemodynamic stress of BAV on those with profound
ventricular dysfunction, however, requires circulatory assistance to permit periprocedural
survival.
Methods: We evaluated the short term safety and efficacy of using Impella left
ventricular assist device in extremely high-risk patient underoing aortic valvulo-
plasty procedure. 13 patients with severe critical aortic stenosis and multiple
co-morbidities underwent BAV at our institute, 53% patients had concomitant
coronary interventions out of which 38% had multivessel PCI . Because of
advanced age, multiple co-morbidities and poor cardiac reserve & hemodynamic
status, the BAV’s were supported with the Impella.We describe a technique in
which a single 14 french retrograde arterial access was obtained and after crossing
the aortic valve, a 0.035 J-wire with LV curve along with a 0.014 Impella wire
was left in the LV cavity. The impella device is primed and loaded on the 0.014
wire ready to go in case of a hemodynamic compromise. After balloon aortic
valvuloplasty with rapid ventricular pacing is done, the Impella LVAD is rapidly
railed into the LV for hemodynamic support.
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